PROCEPT BioRobotics Stock

$40.83

1.83% today

Nasdaq, Aug 18, 08:20 pm CET

ISIN

US74276L1052

Symbol

PRCT

Reports

Quarter | Annual

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

PROCEPT BioRobotics Stock price

$41.59

-0.35 0.83% 5Y

Nasdaq, Closing price Fri, Aug 15 2025

+1.47 3.66%

ISIN

US74276L1052

Symbol

PRCT

Reports

Quarter | Annual

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$2.3b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

8.4 | 7.0

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

75.3%

Return on Equity

-22.7%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$275.0m | $331.2m

EBITDA

$-85.9m | $-39.6m

EBIT

$-91.8m | $-91.0m

Net Income

$-84.2m | -

Free Cash Flow

$-89.3m

Growth (TTM | estimate)

Revenue

55.7% | 47.5%

EBITDA

18.0% | 56.7%

EBIT

16.3% | 5.8%

Net Income

18.9% | -

Free Cash Flow

18.3%

EPS

$-1.5

FCF per Share

Short interest

15.2%

Employees

756

Rev per Employee

$300.0k

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Get Started for Free Today

PROCEPT BioRobotics Stock Analysis

Unlock Scores for Free

??

19 Analysts have issued a PROCEPT BioRobotics forecast:

15x Buy

79%

4x Hold

21%

More details on Analyst Estimates Including Price Targets

19 Analysts have issued a PROCEPT BioRobotics forecast:

Buy

79%

Hold

21%

Analyst Estimates with Stock Price Targets

Financial data from PROCEPT BioRobotics

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	275 275	56% 56% 100%
- Direct Costs	98 98	23% 23% 36%
Gross Profit	176 176	83% 83% 64%
- Selling and Administrative Expenses	203 203	35% 35% 74%
- Research and Development Expense	66 66	16% 16% 24%
EBITDA	-86 -86	18% 18% -31%
- Depreciation and Amortization	5.84 5.84	21% 21% 2%
EBIT (Operating Income) EBIT	-92 -92	16% 16% -33%
Net Profit	-84 -84	19% 19% -31%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

PROCEPT BioRobotics Stock News

Positive

Seeking Alpha

●

4 days ago

Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy

Procept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company's strong revenue and install base growth, favorable reimbursement, and increasing ASPs support my buy rating and $44 fair value estimate. Gross margin expansion is expected from pricing power, scale, and cost control, with br...

Neutral

Seeking Alpha

●

12 days ago

PROCEPT BioRobotics Corporation (PRCT) Q2 2025 Earnings Call Transcript

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Kevin Waters - Executive VP & CFO Larry L. Wood - Independent Director Matthew James Bacso - Vice President of Investor Relations Reza Zadno - President, CEO & Director Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.

Positive

The Motley Fool

●

12 days ago

Procept (PRCT) Q2 Revenue Jumps 48%

Procept BioRobotics (PRCT -5.28%), a medical technology company specializing in robotic surgical systems for benign prostatic hyperplasia (BPH) treatment, posted second-quarter 2025 results on August 6, 2025. The company reported GAAP revenue of $79.2 million, surpassing analyst estimates.

More PROCEPT BioRobotics News

Company Profile

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating BPH. The firm's proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The company was founded by Nikolai Aljuri and Rodney C. Perkins in 2007 and is headquartered in Redwood City, CA.

Head office	United States
CEO	Reza Zadno
Employees	756
Founded	2007
Website	www.procept-biorobotics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now